Gitnux/Report 2026

Trt Industry Statistics

The global testosterone replacement therapy market is estimated at $2.13B in 2026, explore the figures behind growth, companies, and injectables-driven trends.
3Statistics
23Sources
1Sections
1Visuals
12mRead
Trt Industry Statistics
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 38 days

01 Industry overview

The trt industry at a glance

The global testosterone replacement therapy market is estimated at $2.13 billion in 2026, with North America the largest region and injectables the leading product segment.

$2.13B[3]
Global market size, 2026
3.88%[3]
Forecast CAGR, 2026–2031
42.6%[4]
Injectables share, 2025
5,200+[5]
TRAVERSE trial participants
Market size
The global testosterone replacement therapy market was valued at $2.05 billion in 2025 and is estimated at $2.13 billion in 2026. Mordor Intelligence projects the market to reach $2.57 billion by 2031.[3]
Forecast & CAGR
The market is forecast to grow at a 3.88% compound annual growth rate from 2026 to 2031, reaching $2.57 billion by 2031. Another 2026 estimate places the market at $2.20 billion in 2026 and $2.57 billion in 2030, implying approximately 4.0% annual growth over that period.[3][6]
Market share & regions
North America was the largest regional market in 2025, according to Reports and Data. Mordor Intelligence identifies North America as the largest market and Asia-Pacific as the fastest-growing region in its 2026–2031 outlook.[4][3]
Segmentation
Injectables accounted for 42.6% of market revenue in 2025, making them the largest product category in the Reports and Data assessment. Other major categories include oral formulations, gels and topicals, patches and transdermal products, and implants.[4][5]
Key players & concentration
The competitive set includes AbbVie’s AndroGel, Perrigo’s generic testosterone gel, Endo’s Testim, Fortesta and Aveed, Pfizer’s Depo-Testosterone, and Antares Pharma’s XYOSTED. Mordor Intelligence characterizes market concentration as medium rather than highly concentrated.[7][3]
Pricing
Pricing varies substantially by formulation, insurance coverage and distribution channel. An Oklahoma Medicaid cost comparison listed generic testosterone 1% gel at $216 for a 30-day supply in 2025, while GoodRx reported a typical Depo-Testosterone insurance copay of $60–$80.[8][9]
Trends, drivers & challenges
Growth is supported by increasing diagnosis of hypogonadism, an aging male population, oral and injectable product innovation, and wider use of home-administered therapies. Challenges include adherence burdens for self-injection, blood-pressure monitoring requirements, potential misuse, and continuing scrutiny of prescribing outside approved indications.[6][4][5]
Consumer behavior & competition
Demand is shifting toward convenient administration, including oral capsules, weekly autoinjectors and telehealth-supported treatment. Competition spans low-cost generic injections and gels, branded products differentiated by delivery technology, and online clinics competing on convenience and bundled monitoring.[10][7][11]
M&A
A notable transaction was Grünenthal’s acquisition of the Nebido testosterone-therapy business from Bayer in 2022. The deal expanded Grünenthal’s commercial position in long-acting testosterone replacement products, although no comparably large TRT-specific transaction was identified in the reviewed 2025–2026 sources.[12]
Regulation
FDA-approved testosterone products are indicated for men with low testosterone associated with an underlying medical condition, not solely age-related low levels without an associated condition. In February 2025, FDA removed cardiovascular-risk boxed-warning language while requiring label information on blood-pressure increases; in June 2026, FDA requested further label updates after reviewing newer evidence.[5][13]
Latest news
The most recent major regulatory development identified was FDA’s June 2026 request for class-wide testosterone-label updates. The agency removed the limitation stating that safety and efficacy for age-related hypogonadism had not been established and revised safety language concerning prostate cancer and benign prostatic hyperplasia.[5][13]

02 Ranking

Top 10 Companies in the Trt Industry

The leading companies in the trt industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 18, 2026 · Next review December 18, 2026

Verdict

AbbVie stands out for AndroGel testosterone replacement products because it markets one of the major testosterone replacement products, while Halozyme focuses on XYOSTED because it commercializes a testosterone enanthate injection for TRT with a 37.6% revenue growth rate.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in testosterone gels

    AbbVie

    US

    Ranked #1 · 9.4 · Testosterone gels

    Why we picked it: AbbVie markets AndroGel, one of the major testosterone replacement products, with an operating margin of 24.65% and R&D at 14.88% of revenue.

  2. Leader in testosterone injections

    Halozyme

    US

    Ranked #2 · 9.0 · Testosterone injections

    Why we picked it: Halozyme commercializes XYOSTED, a testosterone enanthate injection for TRT, supported by an operating margin of 33.6% and revenue growth of 37.6%.

  3. Leader in online physician-guided TRT

    Hone Health

    US

    Ranked #4 · 8.8 · Online physician-guided TRT

    Why we picked it: Hone provides online physician-guided testosterone replacement therapy after reviewing labs, combining telehealth treatment with testing review.

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 10 companies in the trt industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

AbbVie

Testosterone gels · US

9.4
2

Halozyme

Testosterone injections · US

9.0
3

Besins Healthcare

Testosterone gels · BE

8.9
4

Hone Health

Online physician-guided TRT · US

8.8
5

Gameday Men's Health

In-person TRT clinics · US

8.7
6

Grünenthal

Nebido testosterone undecanoate, global · DE

8.4
7

Marius Pharmaceuticals

Kyzatrex oral testosterone therapy, US · US

8.2
8

Endo

Testopel and Aveed testosterone therapies, US · US

7.9
9

Defy Medical

Telemedicine hormone replacement clinic, US · US

7.7
10

Viatris

Generic testosterone replacement medicines, global · US

7.4

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 18, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 18). Top 10 companies in the trt industry. In Trt Industry Statistics. Gitnux. https://gitnux.org/trt-industry-statistics/#top-companies

report visual · Projection

Testosterone replacement therapy use rate among U.S. men aged 18–45, any formulation

Testosterone replacement therapy use rate among U.S. men aged 18–45, any formulation grew from 49.2 per 10,000 person-years in 2008 to 118.1 per 10,000 person-years in 2013.

49.2
Start
+19.14%
CAGR · 5y
118
Projected
20082013
source-verifiedstacks.cdc.gov2013

04 Statistics

Market Intelligence

We cataloged 2,900 in-person TRT and hormone clinics across all 50 U.S. states plus Washington, D.C. in July 2026, and tracked 49 online TRT providers in July 2026.

Firm counts and size structure in the trt industry

  • 2,900 in-person TRT and hormone clinics were cataloged across all 50 U.S. states plus Washington, D.C. in July 2026; the directory counts clinics offering TRT or primarily focused on TRT.[1]
  • 223 direct-to-consumer men’s health clinics offering testosterone replacement therapy were identified in the United States in 2021; no newer peer-reviewed national clinic census was identified.[2]
  • 49 online TRT providers were tracked in July 2026, of which 20 published prices publicly and 29 did not publish prices on their websites.[1]

Key questions about the trt industry

What is the global TRT market size in 2026?
The global testosterone replacement therapy market is estimated at $2.13 billion in 2026. It was valued at $2.05 billion in 2025.
How fast is the TRT market expected to grow from 2026 to 2031?
The market is forecast to grow at a 3.88% compound annual growth rate from 2026 to 2031, reaching $2.57 billion by 2031.
Which companies lead the trt industry?
AbbVie stands out for AndroGel testosterone replacement products because it markets one of the major testosterone replacement products, while Halozyme focuses on XYOSTED because it commercializes a testosterone enanthate injection for TRT with a 37.6% revenue growth rate.
What technology or delivery shifts are shaping TRT demand?
Demand is shifting toward convenient administration, including oral capsules, weekly autoinjectors, and telehealth-supported treatment. Home-administered therapies are also expanding.
How is the TRT market structured by product format and competition?
Injectables accounted for 42.6% of market revenue in 2025 and are the leading product segment. Mordor Intelligence characterizes market concentration as medium rather than highly concentrated.
What regulation and labeling updates affect TRT product information?
FDA removed cardiovascular-risk boxed-warning language in February 2025 while requiring label information on blood-pressure increases, and in June 2026 FDA requested further label updates after reviewing newer evidence.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 18). Trt Industry Statistics. Gitnux. https://gitnux.org/trt-industry-statistics
MLA
Samuel Norberg. "Trt Industry Statistics." Gitnux, 18 Nov 2026, https://gitnux.org/trt-industry-statistics.
Chicago
Samuel Norberg. 2026. "Trt Industry Statistics." Gitnux. https://gitnux.org/trt-industry-statistics.